5 May 2021 - - US-based biotechnology company Xilio Therapeutics has appointed Christina Rossi, chief commercial officer of Blueprint Medicines (NASDAQ: BPMC), as a member of its board of directors, the company said.

Rossi joins the Xilio board of directors with 20 years of experience in the pharmaceutical and biotechnology industries.

She is currently the chief commercial officer of Blueprint Medicines and played a critical role in the US launches of Ayvakit and Gavreto in certain genomically defined cancers.

Prior to joining Blueprint Medicines, she served in various roles at Sanofi Genzyme, leading the launches of several new multiple sclerosis therapies, and optimized operations to expand patient access.

Rossi's positions at Sanofi Genzyme included serving as the MS business unit head of North America; vice president, MS sales; and vice president, MS patient and provider services.

Prior to joining Sanofi Genzyme, Rossi held various roles at Biogen, Inc, leading brands and a biosimilar-focused venture. Rossi also consulted within the healthcare practice of Boston Consulting Group.

Rossi holds a Bachelor of Science in biology from Duke University and a Master of Business Administration from Harvard Business School.

Xilio Therapeutics is a privately-held biotechnology company that uses its proprietary technology to engineer potent cancer immunotherapies.

The company's proprietary pipeline includes XTX202, a tumor-selective modified form of IL-2, and XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, as well as tumor-selective IL-12 and IL-15 research programs. Xilio was founded in 2016 and is headquartered in Waltham, Mass.